Human aggrecanase generated synovial fluid fragment levels are elevated directly after knee injuries due to proteolysis both in the inter globular and chondroitin sulfate domains

Osteoarthritis and Cartilage

Volumn 19, Issue 8, 2011, Pages 1047-1057

  Struglics, A ^a   Hansson, M ^a   Lohmander, L S ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Aggrecan; Aggrecanase; Biomarker; Degradation; Synovial fluid; Western blot

Indexed keywords

AGGRECAN; AGGRECANASE; BIOLOGICAL MARKER; CHONDROITIN SULFATE;

ADULT; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; KNEE INJURY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN DOMAIN; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SYNOVIAL FLUID; WESTERN BLOTTING;

ADULT; AGGRECANS; BLOTTING, WESTERN; CARTILAGE, ARTICULAR; CASE-CONTROL STUDIES; CHONDROITIN SULFATES; ENDOPEPTIDASES; FEMALE; HUMANS; KNEE INJURIES; MALE; MIDDLE AGED; PROTEOLYSIS; SENSITIVITY AND SPECIFICITY; SYNOVIAL FLUID; YOUNG ADULT;

EID: 79960325801     PISSN: 10634584     EISSN: 15229653     Source Type: Journal    
DOI: 10.1016/j.joca.2011.05.006     Document Type: Article

References (50)

1. Lohmander L.S., Dahlberg L., Ryd L., Heinegard D. Increased levels of proteoglycan fragments in knee joint fluid after injury. Arthritis Rheum 1989, 32:1434-1442.
2. Lohmander L.S., Hoerrner L.A., Dahlberg L., Roos H., Bjornsson S., Lark M.W. Stromelysin, tissue inhibitor of metalloproteinases and proteoglycan fragments in human knee joint fluid after injury. J Rheumatol 1993, 20:1362-1368.
3. Lohmander L.S., Ionescu M., Jugessur H., Poole A.R. Changes in joint cartilage aggrecan after knee injury and in osteoarthritis. Arthritis Rheum 1999, 42:534-544.
4. Sandy J.D. Proteolytic degradation of normal and osteoarthritic cartilage matrix. Osteoarthritis 2003, 82-92. Oxford University Press, Oxford. K.D. Brandt, M. Doherty, L.S. Lohmander (Eds.).
5. Sandy J.D., Flannery C.R., Neame P.J., Lohmander L.S. The structure of aggrecan fragments in human synovial fluid. Evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the Glu 373-Ala 374 bond of the interglobular domain. J Clin Invest 1992, 89:1512-1516.
6. Lohmander L.S., Neame P.J., Sandy J.D. The structure of aggrecan fragments in human synovial fluid. Evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint injury, and osteoarthritis. Arthritis Rheum 1993, 36:1214-1222.
7. Ilic M.Z., Handley C.J., Robinson H.C., Mok M.T. Mechanism of catabolism of aggrecan by articular cartilage. Arch Biochem Biophys 1992, 294:115-122.
8. Loulakis P., Shrikhande A., Davis G., Maniglia C.A. N-terminal sequence of proteoglycan fragments isolated from medium of interleukin-1-treated articular-cartilage cultures. Putative site(s) of enzymic cleavage. Biochem J 1992, 284(Pt 2):589-593.
9. Tortorella M.D., Pratta M., Liu R.Q., Austin J., Ross O.H., Abbaszade I., et al. Sites of aggrecan cleavage by recombinant human aggrecanase-1 (ADAMTS-4). J Biol Chem 2000, 275:18566-18573.
10. Tortorella M.D., Liu R.Q., Burn T., Newton R.C., Arner E. Characterization of human aggrecanase 2 (ADAM-TS5): substrate specificity studies and comparison with aggrecanase 1 (ADAM-TS4). Matrix Biol 2002, 21:499-511.
11. Fosang A.J., Neame P.J., Hardingham T.E., Murphy G., Hamilton J.A. Cleavage of cartilage proteoglycan between G1 and G2 domains by stromelysins. J Biol Chem 1991, 266:15579-15582.
12. Flannery C.R., Lark M.W., Sandy J.D. Identification of a stromelysin cleavage site within the interglobular domain of human aggrecan. Evidence for proteolysis at this site in vivo in human articular cartilage. J Biol Chem 1992, 267:1008-1014.
13. Bonassar L.J., Frank E.H., Murray J.C., Paguio C.G., Moore V.L., Lark M.W., et al. Changes in cartilage composition and physical properties due to stromelysin degradation. Arthritis Rheum 1995, 38:173-183.
14. Lohmander L.S., Atley L.M., Pietka T.A., Eyre D.R. The release of crosslinked peptides from type II collagen into human synovial fluid is increased soon after joint injury and in osteoarthritis. Arthritis Rheum 2003, 48:3130-3139.
15. Larsson S., Lohmander L.S., Struglics A. Synovial fluid level of aggrecan ARGS fragments is a more sensitive marker of joint disease than glycosaminoglycan or aggrecan levels: a cross-sectional study. Arthritis Res Ther 2009, 11:R92.
16. Sandy J.D., Verscharen C. Analysis of aggrecan in human knee cartilage and synovial fluid indicates that aggrecanase (ADAMTS) activity is responsible for the catabolic turnover and loss of whole aggrecan whereas other protease activity is required for C-terminal processing in vivo. Biochem J 2001, 358:615-626.
17. Struglics A., Larsson S., Pratta M.A., Kumar S., Lark M.W., Lohmander L.S. Human osteoarthritis synovial fluid and joint cartilage contain both aggrecanase- and matrix metalloproteinase-generated aggrecan fragments. Osteoarthritis Cartilage 2006, 14:101-113.
18. Struglics A., Larsson S., Hansson M., Lohmander L.S. Western blot quantification of aggrecan fragments in human synovial fluid indicates differences in fragment patterns between joint diseases. Osteoarthritis Cartilage 2009, 17:497-506.
19. Moller H.J., Larsen F.S., Ingemann-Hansen T., Poulsen J.H. ELISA for the core protein of the cartilage large aggregating proteoglycan, aggrecan: comparison with the concentrations of immunogenic keratan sulphate in synovial fluid, serum and urine. Clin Chim Acta 1994, 225:43-55.
20. Fosang A.J., Last K., Maciewicz R.A. Aggrecan is degraded by matrix metalloproteinases in human arthritis. Evidence that matrix metalloproteinase and aggrecanase activities can be independent. J Clin Invest 1996, 98:2292-2299.
21. Valiyaveettil M., Mort J.S., McDevitt C.A. The concentration, gene expression, and spatial distribution of aggrecan in canine articular cartilage, meniscus, and anterior and posterior cruciate ligaments: a new molecular distinction between hyaline cartilage and fibrocartilage in the knee joint. Connect Tissue Res 2005, 46:83-91.
22. Pratta M.A., Su J.L., Leesnitzer M.A., Struglics A., Larsson S., Lohmander L.S., et al. Development and characterization of a highly specific and sensitive sandwich ELISA for detection of aggrecanase-generated aggrecan fragments. Osteoarthritis Cartilage 2006, 14:702-713.
23. Carter Q.L., Dotzlaf J., Swearingen C., Brittain I., Chambers M., Duffin K., et al. Development and characterization of a novel ELISA based assay for the quantitation of sub-nanomolar levels of neoepitope exposed NITEGE-containing aggrecan fragments. J Immunol Methods 2007, 328:162-168.
24. Sumer E.U., Sondergaard B.C., Rousseau J.C., Delmas P.D., Fosang A.J., Karsdal M.A., et al. MMP and non-MMP-mediated release of aggrecan and its fragments from articular cartilage: a comparative study of three different aggrecan and glycosaminoglycan assays. Osteoarthritis Cartilage 2007, 15:212-221.
25. Swearingen C.A., Carpenter J.W., Siegel R., Brittain I.J., Dotzlaf J., Durham T.B., et al. Development of a novel clinical biomarker assay to detect and quantify aggrecanase-generated aggrecan fragments in human synovial fluid, serum and urine. Osteoarthritis Cartilage 2010, 18:1150-1158.
26. Chockalingam P.S., Sun W., Rivera-Bermudez M.A., Zeng W., Dufield D.R., Larsson S., et al. Elevated aggrecanase activity in a rat model of joint injury is attenuated by an aggrecanase specific inhibitor. Osteoarthritis Cartilage 2011, 19:315-323.
27. Larsson S., Englund M., Struglics A., Lohmander L.S. Association between synovial fluid levels of aggrecan ARGS fragments and radiographic progression in knee osteoarthritis. Arthritis Res Ther 2010, 12:R230.
28. Dufield D.R., Nemirovskiy O.V., Jennings M.G., Tortorella M.D., Malfait A.M., Mathews W.R. An immunoaffinity liquid chromatography-tandem mass spectrometry assay for detection of endogenous aggrecan fragments in biological fluids: use as a biomarker for aggrecanase activity and cartilage degradation. Anal Biochem 2010, 406:113-123.
29. Feissner R., Xiang Y., Kranz R.G. Chemiluminescent-based methods to detect subpicomole levels of c-type cytochromes. Anal Biochem 2003, 315:90-94.
30. Mathrubutham M, Vattem K. Methods and considerations for quantitative Western blotting using SuperSignal® Chemiluminescent Substrates. http://www.piercenet.com/files/AN0012.pdf.
31. Heidebrecht F., Heidebrecht A., Schulz I., Behrens S.E., Bader A. Improved semiquantitative Western blot technique with increased quantification range. J Immunol Methods 2009, 345:40-48.
32. Struglics A., Hansson M. Calpain is involved in C-terminal truncation of human aggrecan. Biochem J 2010, 430:531-538.
33. Struglics A., Larsson S. A comparison of different purification methods of aggrecan fragments from human articular cartilage and synovial fluid. Matrix Biol 2010, 29:74-83.
34. Struglics A., Larsson S., Lohmander L.S. Estimation of the identity of proteolytic aggrecan fragments using PAGE migration and Western immunoblot. Osteoarthritis Cartilage 2006, 14:898-905.
35. Irie K., Uchiyama E., Iwaso H. Intraarticular inflammatory cytokines in acute anterior cruciate ligament injured knee. Knee 2003, 10:93-96.
36. Little C.B., Hughes C.E., Curtis C.L., Janusz M.J., Bohne R., Wang-Weigand S., et al. Matrix metalloproteinases are involved in C-terminal and interglobular domain processing of cartilage aggrecan in late stage cartilage degradation. Matrix Biol 2002, 21:271-288.
37. Sztrolovics R., White R.J., Roughley P.J., Mort J.S. The mechanism of aggrecan release from cartilage differs with tissue origin and the agent used to stimulate catabolism. Biochem J 2002, 362:465-472.
38. Karsdal M.A., Sumer E.U., Wulf H., Madsen S.H., Christiansen C., Fosang A.J., et al. Induction of increased cAMP levels in articular chondrocytes blocks matrix metalloproteinase-mediated cartilage degradation, but not aggrecanase-mediated cartilage degradation. Arthritis Rheum 2007, 56:1549-1558.
39. Lee J.H., Fitzgerald J.B., Dimicco M.A., Grodzinsky A.J. Mechanical injury of cartilage explants causes specific time-dependent changes in chondrocyte gene expression. Arthritis Rheum 2005, 52:2386-2395.
40. Thibault M., Poole A.R., Buschmann M.D. Cyclic compression of cartilage/bone explants in vitro leads to physical weakening, mechanical breakdown of collagen and release of matrix fragments. J Orthop Res 2002, 20:1265-1273.
41. Lin P.M., Chen C.T., Torzilli P.A. Increased stromelysin-1 (MMP-3), proteoglycan degradation (3B3- and 7D4) and collagen damage in cyclically load-injured articular cartilage. Osteoarthritis Cartilage 2004, 12:485-496.
42. Lark M.W., Bayne E.K., Flanagan J., Harper C.F., Hoerrner L.A., Hutchinson N.I., et al. Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints. J Clin Invest 1997, 100:93-106.
43. Lohmander L.S., Englund P.M., Dahl L.L., Roos E.M. The long-term consequence of anterior cruciate ligament and meniscus injuries: osteoarthritis. Am J Sports Med 2007, 35:1756-1769.
44. Frobell R.B., Roos H.P., Roos E.M., Hellio Le Graverand M.P., Buck R., Tamez-Pena J., et al. The acutely ACL injured knee assessed by MRI: are large volume traumatic bone marrow lesions a sign of severe compression injury?. Osteoarthritis Cartilage 2008, 16:829-836.
45. Wilson C.G., Nishimuta J.F., Levenston M.E. Chondrocytes and meniscal fibrochondrocytes differentially process aggrecan during de novo extracellular matrix assembly. Tissue Eng Part A 2009, 15:1513-1522.
46. Fosang A.J., Last K., Stanton H., Weeks D.B., Campbell I.K., Hardingham T.E., et al. Generation and novel distribution of matrix metalloproteinase-derived aggrecan fragments in porcine cartilage explants. J Biol Chem 2000, 275:33027-33037.
47. Malfait A.M., Liu R.Q., Ijiri K., Komiya S., Tortorella M.D. Inhibition of ADAM-TS4 and ADAM-TS5 prevents aggrecan degradation in osteoarthritic cartilage. J Biol Chem 2002, 277:22201-22208.
48. Embry Flory J.J., Fosang A.J., Knudson W. The accumulation of intracellular ITEGE and DIPEN neoepitopes in bovine articular chondrocytes is mediated by CD44 internalization of hyaluronan. Arthritis Rheum 2006, 54:443-454.
49. Ariyoshi W., Knudson C.B., Luo N., Fosang A.J., Knudson W. Internalization of aggrecan G1 domain neoepitope ITEGE in chondrocytes requires CD44. J Biol Chem 2010, 285:36216-36224.
50. Dahlberg L., Ryd L., Heinegard D., Lohmander L.S. Proteoglycan fragments in joint fluid. Influence of arthrosis and inflammation. Acta Orthop Scand 1992, 63:417-423.